Lipids, lipid compositions, and methods of using them
Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.
1. A stealth lipid of formula (XI)
or a salt or pharmaceutically acceptable derivative thereof,
wherein:
Z is a hydrophilic head group component selected from PEG and polymers based on poly(oxazoline), poly(ethyleneoxide), poly(vinyl alcohol), poly(glycerol), poly(N-vinylpyrrolidone), poly[N-(2-hydroxypropyl)methacrylamide] and poly(amino acid)s, wherein the polymer may be linear or branched, and wherein the polymer may be optionally substituted;
wherein Z is polymerized by n subunits;
n is a number-averaged degree of polymerization between 10 and 200 units of Z, wherein n is optimized for different polymer types;
L 1 is an optionally substituted C 1-10 heteroalkylene linker including one, two or more of an ester (e.g., —C(O)O—), succinate (e.g., —O(O)C—CH 2 —CH 2 —C(O)O—)), carbamate (e.g., —OC(O)—NR′—), carbonate (e.g., —OC(O)O—), ketone (e.g., —C—C(O)—C—), carbonyl (e.g., —C(O)—), urea (e.g., —NRC(O)NR′—), amine (e.g., —NR′—), amide (e.g., —C(O)NR′—), imine (e.g., —C(NR′)—), thioether (e.g., —S—), xanthate (e.g., —OC(S)S—), and phosphodiester (e.g., —OP(O) 2 O—); any of which may be substituted by zero, one or more Z groups;
wherein R′ is independently selected from —H, —NH—, —NH 2 , —O—, —S—, a phosphate or an optionally substituted C 1-10 alkylene;
X 1 and X 2 are independently selected from a carbon or a heteroatom selected from —NH—, —O—, —S— or a phosphate; and
A 1 and A 2 are independently selected from a C 6-30 alkyl, C 6-30 alkenyl, and C 6-30 alkynyl, wherein A 1 and A 2 may be the same or different.
2. The stealth lipid, or a salt or pharmaceutically acceptable derivative thereof, according to claim 1 , is of formula (XII)
wherein
PEG is a poly(ethylene glycol) subunit, wherein the PEG may be linear or branched;
n is a number-averaged degree of polymerization between 10 and 200 units of PEG;
L 1 is an optionally substituted C 1-10 heteroalkylene linker containing one, two or more of an ester, succinate, carbamate, carbonate, ketone, carbonyl, urea, amine, amide, imine, thioether, xanthate, and phosphodiester; any of which may be substituted by zero, one or more PEG groups;
X 1 and X 2 are independently selected from carbon or oxygen; and
A 1 and A 2 are independently selected from a C 6-30 alkyl, C 6-30 alkenyl, and C 6-30 alkynyl, wherein A 1 and A 2 may be the same or different.
3. The stealth lipid, or a salt or pharmaceutically acceptable derivative thereof, according to claim 1 or claim 2 , wherein the stealth lipid is selected from:
4. The stealth lipid, or a salt or pharmaceutically acceptable derivative thereof, according to claim 1 or claim 2 , wherein the stealth lipid is
5. A method for the treatment of a disease or condition comprising the step of administering a therapeutically effective amount of a stealth lipid according to claim 1 to a patient in need thereof.
6. The method of claim 5 wherein the disease or condition is a cancer, a disease of the liver, or a disease that is responsive to treatment with an RNAi construct.
7. A method for the treatment of a disease or condition in a subject in need thereof, the method comprising the step of administering a therapeutically effective amount of a biologically active agent in a formulation comprising a stealth lipid according to claim 1 or claim 2 .
8. The method of claim 7 wherein the disease or condition is a tumor, a disease of the liver, or a disease that is responsive to treatment with an RNAi construct.